Legal status · United States
Is Cebranopadol legal in the United States?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
No. Cebranopadol is not approved for any medical use in the United States; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 7 human studies are cited on its profile.
Cebranopadol in the United States at a glance
| Classification | Investigational, not approved |
|---|---|
| Note | A mu-opioid agonist; would be a controlled substance if approved. |
| FDA approval status | Not FDA approved. Two phase 3 acute pain trials completed 2024 to 2025 with no posted results; chronic cancer pain phase 3 terminated for low accrual. No application in openFDA as of September 2026. |
| Human studies cited | 7 of 7 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the Cebranopadol profile, checked against U.S. Food and Drug Administration (FDA) listings at the reviewed date.
What this means
- 01
Cebranopadol is being studied in registered clinical trials but has not received FDA marketing approval in the United States.
- 02
Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.
- 03
Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.
What Cebranopadol is
Not a peptide: a small molecule opioid that also activates the nociceptin peptide receptor. In two head to head healthy volunteer studies it produced less respiratory depression than oxycodone at equal analgesia, and in phase 2 trials it matched or beat morphine and tapentadol. Two phase 3 acute pain trials completed in 2025 and are unpublished. Not approved.
Cebranopadol is in peptide catalogues by mistake, or by association. It is a synthetic small molecule, not a peptide.
Mechanism: 20 ng/mL versus 36 ng/mL); and that its subjective drug liking in recreational opioid users is lower than hydromorphone at doses up to 400 mcg. Its analgesic effect site equilibration is slow, around 8 hours in the 2017 study, which is why phase 2 trials titrated it over weeks.
Regulatory history: Not FDA approved. Two phase 3 acute pain trials completed 2024 to 2025 with no posted results; chronic cancer pain phase 3 terminated for low accrual. No application in openFDA as of September 2026.
How FDA treats this kind of product
Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.
The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for Cebranopadol at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Cebranopadol in other countries
Frequently asked questions
Is Cebranopadol legal in the United States?
No. Cebranopadol is not approved for any medical use in the United States; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 7 human studies are cited on its profile. Note: A mu-opioid agonist; would be a controlled substance if approved.
Can I buy Cebranopadol in the United States?
No approved product exists to buy. In the United States Cebranopadol is classified as "Investigational, not approved", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors. Note: A mu-opioid agonist; would be a controlled substance if approved.
Is Cebranopadol FDA approved?
No. FDA status: Not FDA approved. Two phase 3 acute pain trials completed 2024 to 2025 with no posted results; chronic cancer pain phase 3 terminated for low accrual. No application in openFDA as of September 2026.. Current US classification: "Investigational, not approved". On the evidence, 7 human studies are cited on its profile.
Related compounds in the United States
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Cebranopadol live on its compound profile.
Cebranopadol profileThis page is general information about the regulatory status of Cebranopadol in the United States, current as of Sep 2026. It is not legal advice, and classifications change; check U.S. Food and Drug Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.